Business
Preliminary Results Presented at ASCO Demonstrated Promising Clinical Efficacy with Unesbulin in Leiomyosarcoma Study
- Results highlight strength of PTC Therapeutics' scientific platform in targeting difficult-to-treat rare cancer types - SOUTH PLAINFIELD, N.J., June 3, 2022
About this update from Ptc Therapeutics, Inc.
[{"type":"text","content":"- Results highlight strength of PTC Therapeutics' scientific platform in targeting difficult-to-treat rare cancer types -\nSOUTH PLAINFIELD, N.J., June 3, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced encouraging preliminary safety and efficacy results from its Phase 1B study of unesbulin (PTC596) in advanced leiomyosarcoma (LMS) patients. The results demonstrated that treated patients achieved an 18.2 percent objective response rate and a 51.5 percent disease control rate. In addition, unesbulin was generally well tolerated. The results from the dose escalation study which evaluated unesbulin in combination with dacarbazine (DTIC), will be presented on Saturday, June 4, during the Sarcoma Oral Abstract Session beginning at 1:15 p.m. CDT at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.\n\n \n \n \n \n \n \n\n \n\"The results demonstrated with unesbulin in LMS patients are very promising,\" said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics. \"Leiomyosarcoma is an aggressive soft tissue sarcoma that has significant high unmet medical need, especially for those patients who have relapsed or are refractory to current treatments. We are excited to bring a new chemical entity to the fight against cancer.\"\nThe primary objectives of the study were to determine the recommended Phase 2 dose (RP2D) of unesbulin in combination with DTIC and to characterize the safety profile of the combination. In addition, the secondary objectives included progression free survival and duration of response. Unesbulin 300 mg taken twice a week in combination with DTIC 1,000 mg/m2 every 21 days was established as the RP2D.\n\"Leiomyosarcoma is a particularly aggressive tumor type that desperately requires new treatment options for patients,\" said Brian Van Tine, M.D., Ph.D., Sarcoma Program, Washington University and lead clinical investigator. \"The preliminary results demonstrate promising early efficacy in patients with advanced leiomyosarcoma.\"\nBased on the preliminary data from the Phase 1B study, PTC has initiated the SUNRISE LMS study. SUNRISE LMS is an international, placebo-controlled, registration-directed study comparing the efficacy and safety of unesbulin and DTIC versus placebo and DTIC in patients with advanced LMS who have received ≥1 prior line of syste...